Polgenix

Trevena, originally founded as Polgenix, is a biopharmaceutical company specializing in the discovery and development of G protein-coupled receptor (GPCR) targeted medicines. The company utilizes its proprietary biased ligand platform to develop therapies that selectively engage specific signaling pathways to maximize therapeutic benefit while minimizing side effects. Their lead asset, Olinvyk (oliceridine), received FDA approval for the management of acute pain in hospital or controlled clinical settings. Trevena continues to advance a pipeline of small molecule candidates targeting various GPCRs for conditions such as migraine and neuropathic pain. The company was co-founded by Nobel Laureate Robert Lefkowitz, a pioneer in the field of GPCR research.